| Vaprisol®(conivaptan) |
|
|
|
|
Vaprisol®(conivaptan hydrochloride) ampule |
| NDC Number |
Product Number |
Desc
ription |
Strength |
Concen
tration |
Size |
Unit of Sale |
Closure |
| 0469-1601-04 |
160104 |
SD ampule |
20 mg |
5 mg/mL |
4 mL |
10 |
IV Port |
| 0469-1602-11 |
160211 |
100ml INTRAVIA plastic container |
20 mg |
5 mg/mL |
100 mL |
10 |
IV Port |
|
|
| Each ampule contains: |
| Conivaptan hydrochloride |
20 mg |
| Propylene glycol |
1.2 g |
| ethanol |
0.4 g |
| Water for Injection |
q.s. |
| Lactic acid for pH adjustment |
|
|
Vaprisol® (conivaptan hydrochloride) premixed in 5% Dextrose in INTRAVIA® plastic container |
| NDC Number |
Product Number |
Desc
ription |
Strength |
Concen
tration |
Size |
Unit of Sale |
Closure |
| 0469-1602-11 |
160211 |
100ml INTRAVIA plastic container |
20 mg |
5 mg/mL |
100 mL |
10 |
NA |
|
|
| Each premixed bag contains: |
| Conivaptan hydrochloride |
20 mg |
| Dextrose hydrous, USP |
5 mg |
| Lactic acid for pH adjustment |
|
|
Vaprisol® is a registered trademark of Astellas Pharma Inc. INTRAVIA® is a registered trademark of Baxter International, Inc. (only should be used when referencing Vaprisol (conivaptan hydrochloride injection) Premixed in 5% Dextrose). |
